Emre Kadir Ayan

Emre Kadir Ayan

Auto-generated profile, based on publicly available information

Emre Kadir Ayan

Department of Pharmaceutical Chemistry, Faculty of Pharmacy Suleyman Demirel University Isparta Türkiye

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2025 in Journal of the Indian Chemical Society
Verified
Journal Article
Closed access
EAEmre Kadir Ayan
Emre Kadir Ayan
AEAli ERGÜÇ
Ali ERGÜÇ
Muhammed Tilahun MuhammedMuhammed Tilahun Muhammed
Muhammed Tilahun Muhammed
EAEge Arzuk
Ege Arzuk
ZSZeynep SOYER
Zeynep SOYER

25 August 2026 in Drug Development Research
Verified
Journal Article
Open access
GAGülnur Arslan
Gülnur Arslan
BGBaşak Gökçe
Başak Gökçe
Muhammed Tilahun MuhammedMuhammed Tilahun Muhammed
Muhammed Tilahun Muhammed
EAEmre Kadir Ayan
Emre Kadir Ayan
AÖAzime Berna Özçelik
Azime Berna Özçelik
In this study, 12 novel sulfonamide derivatives incorporating 2‐amino‐1,3,4‐oxadiazole and 1,3‐benzazol‐2(3 H )‐one scaffolds were synthesized and structurally characterized using 1 H NMR, 13 C NMR, and LC–MS analyses. Their inhibitory activities were evaluated against acetylcholinesterase (AChE), butyrylcholinesterase (BChE), carbonic anhydrase I and II (CA I and CA II), and α‐glucosidase. Owing to their potent inhibitory profiles, enzyme kinetic studies were performed to determine inhibition constants ( Ki ) and inhibition mechanisms. The synthesized compounds exhibited potent nanomolar cholinesterase inhibition. Compound 5b was identified as the most active AChE inhibitor (IC 50 = 32.6 ± 2.6 nM; Kᵢ = 7.1 ± 0.6 nM), acting through a competitive inhibition mechanism, whereas compound 5g showed the strongest BChE inhibition (IC 50 = 34.6 ± 2.8 nM; Kᵢ = 8.4 ± 0.8 nM) with a mixed‐type inhibition profile. The derivatives also displayed significant carbonic anhydrase inhibition, with compound 6d emerging as the most potent inhibitor, particularly against CA II (IC 50 = 0.9 ± 0.06 μM; Kᵢ = 0.43 ± 0.037 μM), while exhibiting competitive inhibition and strong activity against both CA isoforms. In contrast, α‐glucosidase inhibition was generally weak, with compound 5d showing the highest activity (IC 50 = 250.5 ± 21.32 μM). Molecular docking studies revealed favorable binding interactions within the catalytic sites of cholinesterase and carbonic anhydrase enzymes, while 200 ns length molecular dynamics simulations confirmed the stability of representative protein–ligand complexes. In silico ADMET and drug‐likeness predictions using SwissADME and pkCSM indicated generally acceptable oral drug‐likeness. Compound 6c exhibited the most balanced predicted pharmacokinetic profile, whereas 6d , despite its excellent enzyme inhibition, showed potential limitations associated with higher polarity, limited predicted blood–brain barrier penetration, and predicted toxicity risks. Overall, these findings identify the synthesized sulfonamide derivatives as promising scaffolds for the further development of multifunctional cholinesterase and carbonic anhydrase inhibitors.